RxDoctor Payments DataLook up a doctor →

John Hardy, MD

Psychiatry · Pueblo, CONPI 1619032182

Payments from drug & device makers

$886,580in general payments, 2019–2025

Across 1,282 payments — averaging $691.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$579K
  • Avanir Pharmaceuticals, Inc.$78K
  • E.r. Squibb & Sons, L.L.C.$66K
  • AbbVie$42K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$38K
  • Eisai Inc.$20K
  • plus $64K from 19 others

What the payments were for

  • Consulting fees$61,5217%
  • Speaking & faculty fees$636,15077%
  • Travel & lodging$103,37812%
  • Food & beverage$26,9543%
  • Education$4130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$886,580 in reported general payments places this provider in the 95th percentile of 559 psychiatry providers in Colorado.

See all psychiatry providers in Colorado

Medicare billing

Part B allowed, 2024
$51,049
Medicare patients
165
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate24$192,842
VraylarCariprazine Hcl68$96,726
TrintellixVortioxetine Hydrobromide122$85,806
LybalviOlanzapine/Samidorphan Malate26$40,683
RexultiBrexpiprazole25$35,825
NuedextaDextromethorphan Hbr/Quinidine12$19,519
QuviviqDaridorexant Hcl24$11,138
Duloxetine Hcl265$8,003
Lamotrigine502$6,268
Aripiprazole196$5,409
VyvanseLisdexamfetamine Dimesylate12$4,867
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine168$4,793
Olanzapine110$4,624
Vilazodone Hcl26$4,029
Modafinil28$3,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$578,737$192,84224 claims
AbbVieVraylar$41,576$96,72668 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$250$90,673134 claims
Alkermes, Inc.Lybalvi$13,612$40,68326 claims
Otsuka America Pharmaceutical, Inc.Rexulti$277$35,82525 claims
Avanir Pharmaceuticals, Inc.Nuedexta$77,985$19,51912 claims
Idorsia Pharmaceuticals US IncQuviviq$42$11,13824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 559 psychiatry providers in Colorado.

Other psychiatry in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →